Login to Your Account

Pharma: Other News To Note

Thursday, December 13, 2012

• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, and H. Lundbeck A/S, of Copenhagen, Denmark, said the FDA accepted for filing the companies' new drug application for vortioxetine for the treatment of major depressive disorder in adults. A PDUFA date of Oct. 2, 2013, is anticipated. Takeda and Lundbeck also disclosed the proposed brand name of Brintellix for vortioxetine.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription